Mary Afrane1, Leah Sera2, Holly M Holmes3, Mary L McPherson4. 1. Department of Pharmacy Services, MedStar Union Memorial Hospital, Baltimore, MD, USA. 2. Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD, USA lsera@rx.umaryland.edu. 3. Department of General Internal Medicine/Healthy Aging Clinic, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Abstract
PURPOSE: End-stage chronic obstructive pulmonary disease (COPD) presents health care providers with challenges of providing optimal palliative care for patients who follow a less predictable trajectory. The objectives of this study were to evaluate medications being prescribed to patients with end-stage COPD, compared to recommendations made by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, and to determine which medications were provided by the hospice organization. METHODS: We retrospectively reviewed our database for medications pertaining to COPD management as stated in the GOLD criteria or those used for symptoms associated with end of life. RESULTS: A total of 745 patients met inclusion criteria, and approximately 63% were prescribed opioids. Prescribing rates for oxygen, short-acting β2-agonists, and short-acting anticholinergics were 37%, 33%, and 31%, respectively. Systemic and inhaled corticosteroids were prescribed at higher rates of 20% and 18% compared to long-acting bronchodilators. DISCUSSION: Medications used for COPD exacerbation management were prescribed at higher rate than those used for maintenance treatment.
PURPOSE: End-stage chronic obstructive pulmonary disease (COPD) presents health care providers with challenges of providing optimal palliative care for patients who follow a less predictable trajectory. The objectives of this study were to evaluate medications being prescribed to patients with end-stage COPD, compared to recommendations made by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, and to determine which medications were provided by the hospice organization. METHODS: We retrospectively reviewed our database for medications pertaining to COPD management as stated in the GOLD criteria or those used for symptoms associated with end of life. RESULTS: A total of 745 patients met inclusion criteria, and approximately 63% were prescribed opioids. Prescribing rates for oxygen, short-acting β2-agonists, and short-acting anticholinergics were 37%, 33%, and 31%, respectively. Systemic and inhaled corticosteroids were prescribed at higher rates of 20% and 18% compared to long-acting bronchodilators. DISCUSSION: Medications used for COPD exacerbation management were prescribed at higher rate than those used for maintenance treatment.
Authors: Paul N Lanken; Peter B Terry; Horace M Delisser; Bonnie F Fahy; John Hansen-Flaschen; John E Heffner; Mitchell Levy; Richard A Mularski; Molly L Osborne; Thomas J Prendergast; Graeme Rocker; William J Sibbald; Benjamin Wilfond; James R Yankaskas Journal: Am J Respir Crit Care Med Date: 2008-04-15 Impact factor: 21.405
Authors: Amy P Abernethy; Christine F McDonald; Peter A Frith; Katherine Clark; James E Herndon; Jennifer Marcello; Iven H Young; Janet Bull; Andrew Wilcock; Sara Booth; Jane L Wheeler; James A Tulsky; Alan J Crockett; David C Currow Journal: Lancet Date: 2010-09-04 Impact factor: 79.321
Authors: Geert N Rootmensen; Anton R J van Keimpema; Henk M Jansen; Rob J de Haan Journal: J Aerosol Med Pulm Drug Deliv Date: 2010-10 Impact factor: 2.849
Authors: Denis E O'Donnell; Shaw Aaron; Jean Bourbeau; Paul Hernandez; Darcy D Marciniuk; Meyer Balter; Gordon Ford; Andre Gervais; Rogers Goldstein; Rick Hodder; Alan Kaplan; Sean Keenan; Yves Lacasse; Francois Maltais; Jeremy Road; Graeme Rocker; Don Sin; Tasmin Sinuff; Nha Voduc Journal: Can Respir J Date: 2007-09 Impact factor: 2.409